Syntara Ltd
ASX:SNT

Watchlist Manager
Syntara Ltd Logo
Syntara Ltd
ASX:SNT
Watchlist
Price: 0.066 AUD 6.45%
Market Cap: 90.6m AUD
Have any thoughts about
Syntara Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-6.1
Current
-4.5
Median
13.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-6.1
=
Enterprise Value
85.8m AUD
/
EBITDA
-14.1m AUD
All Countries
Close
Market Cap EV/EBITDA
AU
Syntara Ltd
ASX:SNT
89.3m AUD -6.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 459 134.4
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 48.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 20.2
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 11.5
US
Merck & Co Inc
NYSE:MRK
251.6B USD 10.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 9.8
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 168.9
CH
Novartis AG
SIX:NOVN
171.3B CHF 9.4
US
Pfizer Inc
NYSE:PFE
151.4B USD 10.6
EBITDA Growth EV/EBITDA to Growth
AU
Syntara Ltd
ASX:SNT
Average EV/EBITDA: 459.5
Negative Multiple: -6.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-8.5
2-Years Forward
EV/EBITDA
5.8
3-Years Forward
EV/EBITDA
-16.9

See Also

Discover More